J95.84 Transfusion-related acute lung injury (TRALI)

Name of the Condition

• Transfusion-Related Acute Lung Injury (TRALI) (ICD-10 Code J95.84)

Summary

This code describes a rare but serious complication of blood transfusion characterized by acute respiratory distress, typically occurring within 6 hours of transfusion. TRALI involves non-cardiogenic pulmonary edema, leading to hypoxemia and bilateral lung infiltrates, often requiring respiratory support.

Causes

TRALI is primarily triggered by antibodies in donor blood (e.g., anti-leukocyte antibodies) or biologically active substances (e.g., lipids) that activate recipient neutrophils, causing endothelial damage and increased pulmonary capillary permeability. It may also result from recipient antibodies reacting with donor white blood cells.

Risk Factors

• Recipients of plasma-rich blood products (e.g., fresh frozen plasma, platelets)
• History of prior transfusions or pregnancy (increased antibody exposure)
• Critical illness or immunocompromised states
• Patients with active infections or sepsis
• Use of blood products from female donors with pregnancy history

Symptoms

• Sudden onset of shortness of breath or dyspnea
• Hypoxemia (low blood oxygen levels)
• Bilateral pulmonary infiltrates on chest imaging
• Fever or hypotension in severe cases
• Possible tachypnea or respiratory distress

Diagnosis

Clinical assessment of acute respiratory symptoms following transfusion, excluding other causes (e.g., fluid overload, infection). Chest imaging (X-ray or CT) to confirm bilateral infiltrates. Arterial blood gas analysis to assess oxygenation. Pulmonary artery catheterization may be used to rule out cardiogenic edema.

Treatment Options

Supportive care, including supplemental oxygen or mechanical ventilation. Discontinuation of the transfusion. Diuretics are generally avoided unless fluid overload is confirmed. Corticosteroids or other immunomodulators may be considered in severe cases.

Prognosis and Follow-Up

Most patients recover within 48–96 hours with appropriate support, but mortality can occur in severe cases. Follow-up includes monitoring respiratory function and oxygenation until symptoms resolve. Long-term lung function is typically preserved in survivors.

Complications

• Acute respiratory distress syndrome (ARDS)
• Multi-organ failure in severe cases
• Prolonged mechanical ventilation
• Death in rare instances

Lifestyle & Prevention

• Use leukoreduced blood products to reduce antibody-mediated risk.
• Screen donors for high-titer antibodies (e.g., anti-HLA, anti-neutrophil).
• Avoid transfusing plasma from multiparous female donors when possible.
• Implement strict transfusion protocols to minimize unnecessary transfusions.

When to Seek Professional Help

Seek immediate medical attention if respiratory distress, hypoxemia, or chest discomfort occurs during or after a blood transfusion. Early intervention improves outcomes.

Tips for Medical Coders

Document the timing of symptom onset relative to transfusion (within 6 hours is typical for TRALI). Include details on product type (e.g., plasma, platelets) and any donor screening results if available. Differentiate from other transfusion reactions (e.g., febrile non-hemolytic, allergic) by noting the acute lung injury component. Ensure clinical correlation with imaging and lab findings.